Mission BioCapital
Mission BioCapital is a life science venture capital firm that invests in early-stage companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Mission BioCapital Information
Geographic Data
Address: 139 Main Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$275M
Social
Twitter
Linkedin
Crunchbase
Metrics
1,345,266Website Global Rank
21,008Website Monthly Traffic
Twitter Followers
Description
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they are known by leaders of portfolio companies for the expertise and deep support they provide.
Contact Phone:
+16178123350
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2019 | Tangible Science | Venture Round | 0 |
| 11/2017 | Bolt Threads | Series D | 123M |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 4/2017 | Circle Pharma | Series A | 0 |
| 6/2017 | Redwood Bioscience | Venture Round | - |
| 1/2019 | Photoswitch Biosciences | Venture Round | - |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 5/2020 | QurAlis | Series A | 0 |
| 6/2019 | Vedere Bio ll | Series A | 21M |
| 8/2017 | Atreca | Series B | 35M |
| 6/2019 | Vaxess Technologies | Series A | 8.2M |
| 1/2017 | SiteOne Therapeutics | Series B | 0 |
| 1/2022 | AmbAgon Therapeutics | Series A | 0 |
| 1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
| 12/2021 | Tune Therapeutics | Series A | 40M |
| 4/2018 | GraphWear Technologies | Series A | 0 |
| 5/2022 | Nuvig Therapeutics | Series A | 47M |
| 6/2017 | Zephyrus Biosciences | Venture Round | - |
| 10/2017 | Epiodyne | Venture Round | 5.8M |
| 1/2019 | Nobell Foods | Venture Round | - |
| 11/2018 | QurAlis | Seed Round | 5.5M |
| 6/2021 | Glycomine | Series B | 0 |
| 8/2019 | Glycomine | Series B | 0 |
| 7/2018 | Cereius | Series A | 6.5M |
| 6/2017 | Vivace Therapeutics | Series B | 25M |
| 3/2018 | ViewPoint Therapeutics | Series B | 0 |
| 3/2021 | Mediar Therapeutics | Seed Round | - |
| 5/2017 | Symic Biomedical | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 1/2023 | Vaxess Technologies | Series B | 0 |
| 7/2021 | Shape Therapeutics | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 11/2019 | Arkuda Therapeutics | Series A | 44M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 10/2020 | Dren Bio | Series A | 0 |
| 4/2014 | Sentieon | Series A | 0 |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 10/2021 | GraphWear Technologies | Series B | 0 |
| 12/2018 | Zymergen | Series C | 400M |
| 11/2019 | Shape Therapeutics | Series A | 35.5M |
| 9/2017 | Mitokinin | Series A | - |
| 10/2019 | Wildtype | Series A | 12.5M |
| 6/2020 | Symbiome | Venture Round | 7.2M |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 4/2019 | Nocion Therapeutics | Series A | 0 |
| 12/2018 | Invenio Imaging | Venture Round | 3.5M |
| 1/2018 | True North Therapeutics | Venture Round | - |
| 1/2019 | Telo Therapeutics | Venture Round | - |
| 1/2018 | Magnap | Venture Round | - |
| 3/2019 | Alessa Therapeutics | Venture Round | 3M |
| 1/2018 | Cell Design Labs | Venture Round | - |
| 11/2022 | Vaxess Technologies | Series B | 0 |
| 8/2018 | Principia Biopharma | Venture Round | 50M |
| 6/2022 | Dren Bio | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 1/2018 | Avexegen Therapeutics | Venture Round | - |
| 9/2020 | Totient | Seed Round | 0 |
| 1/2017 | iPierian | Venture Round | - |
| 5/2021 | Vedere Bio ll | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2022 | Nuvig Therapeutics | Series A | 0 |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 1/2022 | AmbAgon Therapeutics | Series A | 0 |
| 12/2021 | Tune Therapeutics | Series A | 0 |
| 10/2021 | GraphWear Technologies | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 7/2021 | Shape Therapeutics | Series B | 0 |
| 6/2021 | Glycomine | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
